BRAF and non-small cell lung carcinoma: In addition to its role in bortezomib resistance in MM, SSP’s was also found to contribute to the resistance against BRAF inhibitors used to treat cancers expressing V600E BRAF mutation, such as melanoma, pancreatic and non-small cell lung cancer cells [38].